Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FLT 201

Next Previous
Search
Drug Profile

FLT 201

Alternative Names: FLT-200; FLT-201; FLT200/201

Latest Information Update: 29 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University College London
  • Developer Spur Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference; Glucosylceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gaucher's disease type I
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Gaucher's disease type I

Most Recent Events

  • 23 Oct 2024 Efficacy, adverse events and pharmacodynamics data from the phase I/II GALILEO-1 trial in Gaucher’s disease type I released by Spur Therapeutics
  • 08 Jul 2024 Efficacy and adverse events data from phase-I/II GALILEO-1 trial released by Spur Therapeutics
  • 08 Jul 2024 Spur Therapeutics completes enrolment in the phase-I/II GALILEO-1 trial for Gaucher's disease in USA, Brazil, Germany, Israel, Spain, Paraguay and United Kingdom (IV) (NCT05324943)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top